JPH1160504A - Tablet composition - Google Patents
Tablet compositionInfo
- Publication number
- JPH1160504A JPH1160504A JP9237710A JP23771097A JPH1160504A JP H1160504 A JPH1160504 A JP H1160504A JP 9237710 A JP9237710 A JP 9237710A JP 23771097 A JP23771097 A JP 23771097A JP H1160504 A JPH1160504 A JP H1160504A
- Authority
- JP
- Japan
- Prior art keywords
- tablet composition
- keishi
- san
- extract
- saiko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は薬効成分の溶出性を
向上させた錠剤組成物に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a tablet composition having improved dissolution of a medicinal ingredient.
【0002】[0002]
【従来の技術】薬物の中でも、例えばクロラムフェニコ
ール、フェナセチン、プレドニゾロン、スピロノラクト
ン、ジアゼパム、フェニトイン、ジクマロールやジゴキ
シン等は、溶出性の悪い、水に灘溶性のものとして知ら
れていた。2. Description of the Related Art Among drugs, for example, chloramphenicol, phenacetin, prednisolone, spironolactone, diazepam, phenytoin, dicumarol and digoxin have been known as poorly dissolving and water-soluble in water.
【0003】従来、上記のような溶出性の悪い薬物につ
いての対応策としては、有効成分そのものを化学修飾し
て溶出性を改善する方法や、製剤処方中に加える添加
剤、例えば崩壊剤の種類や配合量を吟味したり、界面活
性剤等を添加したりして、溶出性を改善する方法が採用
されていた。[0003] Conventionally, as a countermeasure for a drug having poor dissolution as described above, a method of improving the dissolution by chemically modifying the active ingredient itself, an additive to be added to a pharmaceutical formulation, for example, a type of disintegrant In addition, a method has been adopted in which the dissolution property is improved by examining the amount and the amount of the mixture or adding a surfactant or the like.
【0004】[0004]
【発明が解決しようとする課題】しかしながら、有効成
分そのものを化学修飾して溶出性を改善する方法には、
その工程が増えることによるコストアップばかりでな
く、手間や収率等の問題があり、特に有効成分が天然物
由来の成分である場合には、当該有効成分の原価が比較
的高く、且つ、化学修飾のための反応によっては目的物
の収率が低いために、この問題は深刻である場合が多
い。However, methods for improving the dissolution property by chemically modifying the active ingredient itself include:
Not only does the cost increase due to an increase in the number of steps, but also there are problems such as labor and yield. Particularly when the active ingredient is a component derived from a natural product, the cost of the active ingredient is relatively high, and chemical This problem is often serious due to the low yield of the desired product depending on the modification reaction.
【0005】又、崩壊剤等を製剤処方中に添加する方法
にも、製剤化に用いるカルボキシメチルセルロース、ク
ロスカルメロースナトリウムや部分α化デンプン等の崩
壊剤が高価であって、コストアップにつながるという問
題や、製剤化工程への悪影響(造粒性や打錠性が低下す
る)という問題がある。[0005] In addition, the method of adding a disintegrant or the like to a pharmaceutical formulation also requires that disintegrants such as carboxymethylcellulose, croscarmellose sodium and partially pregelatinized starch used in the formulation are expensive, leading to an increase in cost. There is a problem and an adverse effect on the formulation process (granulation and tableting properties are reduced).
【0006】このように、溶出性についてその改善が切
望されているにもかかわらず、実際には容易ではなかっ
た。[0006] As described above, in spite of a desire for improvement in dissolution properties, it has not been easy in practice.
【0007】本発明は、上記のような従来技術の難点を
解消し、薬効成分の溶出性を向上させた錠剤組成物を提
供することを目的としてなされた。[0007] The present invention has been made to solve the above-mentioned disadvantages of the prior art and to provide a tablet composition having improved dissolution of a medicinal ingredient.
【0008】[0008]
【課題を解決するための手段】上記目的を達成するため
に本発明が採用した錠剤組成物の構成は、例えば日本薬
局方収載の崩壊試験において、崩壊時間が5分以上であ
る錠剤組成物に対し、炭酸水素ナトリウムを配合するこ
とにより、薬効成分の溶出性を向上させたことを特徴と
するものである。Means for Solving the Problems To achieve the above object, the composition of the tablet composition employed in the present invention is, for example, a tablet composition having a disintegration time of 5 minutes or more in a disintegration test described in the Japanese Pharmacopoeia. On the other hand, the compound is characterized in that the dissolution property of a medicinal component is improved by blending sodium hydrogen carbonate.
【0009】[0009]
【発明の実施の形態】以下に本発明を詳細に説明する。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below in detail.
【0010】本発明は、上記のように炭酸水素ナトリウ
ムを配合することにより、薬効成分の溶出性を向上させ
た錠剤組成物であり、この炭酸水素ナトリウムについて
は、制酸剤又はアシドーシス抑制剤として医薬品の組成
中に含有されていることが知られており、又、製剤原料
としても使用されているが、それは発泡性薬剤の基剤中
に含有される場合が一般である。[0010] The present invention is a tablet composition in which the dissolution property of a medicinal component is improved by blending sodium hydrogen carbonate as described above. This sodium hydrogen carbonate is used as an antacid or an acidosis inhibitor. It is known that it is contained in the composition of a drug and is also used as a raw material for a drug, but it is generally contained in the base of an effervescent drug.
【0011】本発明は特に、日本薬局方収載の崩壊試験
において、崩壊時間が5分以上である錠剤組成物、中で
も、この崩壊試験の規定(素錠で30分以内)に適応し
ない或いは適応困難な錠剤組成物に対して適用して有効
である。The present invention is particularly applicable to tablet compositions having a disintegration time of 5 minutes or more in the disintegration test described in the Japanese Pharmacopoeia, in particular, not applicable or difficult to comply with the rules of this disintegration test (within 30 minutes for uncoated tablets). It is effective when applied to various tablet compositions.
【0012】本発明の錠剤組成物における薬効成分とし
ては、特に制限はないが、植物エキスや漢方エキス等の
天然物由来成分を例示することができる。尚、この天然
物由来成分は、1種類であっても、2種以上であっても
差し支えない。The medicinal component in the tablet composition of the present invention is not particularly limited, and examples thereof include components derived from natural products such as plant extracts and Chinese herbal extracts. In addition, the natural product-derived component may be of one type or two or more types.
【0013】上記植物エキスとしては、例えばセンナエ
キス、ニンジンエキス、甘草エキス、芍薬エキス、サイ
シンエキス、ビャクシエキス、シンイエキス、ショウマ
エキスやオウギエキス等を挙げることができるが、これ
に制限されることはない。Examples of the plant extract include, but are not limited to, senna extract, carrot extract, licorice extract, peony extract, sycin extract, juniper extract, shin yi extract, ginger extract, and ogi extract. .
【0014】又、上記漢方エキスとしては、例えば、葛
根湯、葛根湯加川きゅう辛夷、乙字湯、安中散、十味敗
毒湯、八味地黄丸、大柴胡湯、小柴胡湯、柴胡桂枝湯、
柴胡加竜骨牡蛎湯、半夏瀉心湯、黄連解毒湯、半夏厚朴
湯、五苓散、小青竜湯、防己黄ぎ湯、消風散、当帰芍薬
散、加味逍遥散、桂枝茯苓丸、桂枝加竜骨牡蛎湯、麻黄
湯、麦門冬湯、四逆散、苓桂じゅつ甘湯、補中益気湯、
桂枝湯、七物降下湯、十全大補湯、荊芥連翹湯、清上防
風湯、防風通聖散、女神散、芍薬甘草湯、平胃散、大黄
甘草湯、当帰飲子、六味丸、治打撲一方、小建中湯、大
建中湯、辛夷清肺湯、牛車腎気丸、柴苓湯、茯苓飲合半
夏厚朴湯、黄連湯、当帰建中湯、桂枝茯苓丸加よく苡
仁、麻子仁丸、麻黄附子細辛湯、桂枝加芍薬大黄湯、清
暑益気湯、桔梗湯等を挙げることができるが、これに制
限されることはない。[0014] Examples of the Kampo extract include Kakkonto, Kakkonyu Kagawa Kyuhoshii, Otoji-yu, Annakasan, Jumi-toxin-to, Hachimi-jio-maru, Dai-saiko-to, Sho-saiko-to, Saiko-keishi Hot water,
Saiko-ka-ryukotsuboreito, Hangeshashinto, Oren-dokuto, Hangesatsu-koboku-to, Gorei-san, Shosei-ryu-to, Koki-ki-go-to, Shofu-san, Tokishakuyaku-san, Kami-shoyo-san, Keishi-sho Bukuryo-gan, Keishika-ryukotsuboreito, Mao-to, Bakumondoto, Shigyakusan, Ryokei-jutsu-kanto, Hochu-ekki-to,
Keishi-to, Shichimono-descent-yu, Juzen-taiho-to, Jingaku-ryo-to, Seiki-kami-hofu-to, Bofu-tsu-sei-san, Megami-san, Shakuyaku-kanzo-to, Hira-gasan-san, Dai-o-kanzo-to, Toki-in-ko, Rokumi-maru On the other hand, Shokenchuto, Daikenchuto, Shinseiseito, Gyusha-Nekikimaru, Saireito, Bukuryo-chonai-kokakuto, Orento, Tokikenchuto, Keishibukuryomaru In addition, there may be mentioned, for example, but not limited to, okuinin, asojinmaru, mao-bushi-saishin-to, keishi-ka-shakuyaku-dai-o-to, seika-ekki-to, kikyo-to.
【0015】尚、上記漢方エキスは、生薬を抽出し、濃
縮及び乾燥をして得られたもので、一般的に結合能が高
く、吸湿しやすいというように、粉体の物性としてはか
なり取り扱いにくいものである。又、一日あたりの服用
量も、多いものでは6000mgと、新薬系医薬品の有
効成分の服用量とは比較にならないほど多い。すなわ
ち、このような漢方エキスを製剤する場合は、できるだ
け服用感を向上させる目的で賦形剤の量を少なく抑える
必要があり、従って、日本薬局方収載の崩壊試験におい
て崩壊時間が5分以上となることが多く認められるもの
である。The Kampo extract is obtained by extracting, concentrating and drying a crude drug. Generally, it has a high binding ability and easily absorbs moisture. It is difficult. In addition, the daily dose is as high as 6000 mg, which is much higher than the dose of the active ingredient of the new drug. That is, when preparing such a Kampo extract, it is necessary to reduce the amount of excipients in order to improve the feeling of taking as much as possible. Therefore, in the disintegration test listed in the Japanese Pharmacopoeia, the disintegration time is 5 minutes or more. Is often recognized.
【0016】本発明において、上記有効成分と共に用い
られる炭酸水素ナトリウムの配合量としては、有効成分
の重量に対し、好ましくは3%以上、特に好ましくは7
%から70%という範囲を例示することができ、炭酸水
素ナトリウムの配合量が3%未満であるとその添加の効
果がさほど認められない。In the present invention, the amount of sodium bicarbonate used together with the above-mentioned active ingredient is preferably 3% or more, particularly preferably 7%, based on the weight of the active ingredient.
% To 70%. When the amount of sodium hydrogencarbonate is less than 3%, the effect of the addition is not so noticeable.
【0017】本発明の錠剤組成物に対しては、必要に応
じ、適宜に賦形剤や滑沢剤等を添加することができ、こ
れらには、乳糖、アメ粉、白糖等の糖類;コーンスター
チ、デキストリン、PCS等のデンプン類;結晶セルロ
ース、ヒドロキシプロピルセルロース等のセルロース
類;メタケイ酸アルミン酸マグネシウム、ステアリン酸
マグネシウム、夕ルク、酸化チタン等の無機物質が含ま
れる。Excipients and lubricants can be appropriately added to the tablet composition of the present invention, if necessary, such as sugars such as lactose, candy powder and sucrose; corn starch. , Dextrin, PCS and the like; starches such as crystalline cellulose and hydroxypropyl cellulose; and inorganic substances such as magnesium aluminate metasilicate, magnesium stearate, nylon and titanium oxide.
【0018】又、本発明の錠剤組成物を製剤する方法に
も特に制限はなく、一般的な打錠機を使用することがで
きる。The method for preparing the tablet composition of the present invention is not particularly limited, and a general tableting machine can be used.
【0019】[0019]
【実施例】次に本発明を実施例により詳細に説明する。Next, the present invention will be described in detail with reference to examples.
【0020】実施例1−1 防風通聖散エキス錠 防風通聖散エキス末 78.12重量% 炭酸水素ナトリウム 10.44重量%(防風通
聖散エキス末に対して約13.36%) 結晶セルロース 10.74重量% ステアリン酸マグネシウム 0.70重量% 上記原料をそれぞれ篩を用いて篩過し、上記配合比に基
づいて秤量した後、混合したものを打錠用混合末とし、
これを打錠機を用いて錠剤化した。Example 1-1 Windproof Tsushosan Extract Powder Windproof Tsushosan Extract Powder 78.12% by weight Sodium bicarbonate 10.44% by weight (about 13.36% based on Windproof Tsushosan Extract powder) Cellulose 10.74% by weight Magnesium stearate 0.70% by weight Each of the above-mentioned raw materials was sieved using a sieve, weighed based on the above blending ratio, and the mixture was used as a mixed powder for tableting.
This was tableted using a tableting machine.
【0021】上記のようにして得られた錠剤につき、以
下の条件の下、日本薬局方収載の溶出試験法の第2法
(パドル法)により、溶出試験を実施した。結果を図1
に示した。 試験液 :精製水(37℃±0.5℃) 試験液量 :900mL パドル回転数:50rpm 検出器 :UVThe tablets obtained as described above were subjected to a dissolution test by the second method (paddle method) of the dissolution test published in the Japanese Pharmacopoeia under the following conditions. Figure 1 shows the results
It was shown to. Test solution: Purified water (37 ° C ± 0.5 ° C) Test solution volume: 900 mL Paddle rotation speed: 50 rpm Detector: UV
【0022】実施例1−2〜1−4及び比較例1 炭酸水素ナトリウムと結晶セルロースの重量を以下の表
1のように変えた以外は実施例1−1と同様にして錠剤
を得、溶出試験を実施した。結果を図1に示した。Examples 1-2 to 1-4 and Comparative Example 1 Tablets were obtained and dissolved in the same manner as in Example 1-1 except that the weights of sodium hydrogen carbonate and crystalline cellulose were changed as shown in Table 1 below. The test was performed. The results are shown in FIG.
【0023】[0023]
【表1】 [Table 1]
【0024】実施例2−1 五苓散料エキス錠 五苓散料エキス末 68.63重量% 炭酸水素ナトリウム 20.57重量%(五苓散
料エキス末に対して約29.97%) 結晶セルロース 10.30重量% ステアリン酸マグネシウム 0.50重量% 上記原料を用い、実施例1−1と同様にして錠剤を得、
溶出試験を実施した。結果を図2に示した。Example 2-1 Gorei-san extract tablets Gorei-san extract powder 68.63% by weight Sodium bicarbonate 20.57% by weight (about 29.97% based on Gorei-san extract powder) Cellulose 10.30% by weight Magnesium stearate 0.50% by weight Using the above raw materials, tablets were obtained in the same manner as in Example 1-1.
A dissolution test was performed. The results are shown in FIG.
【0025】実施例2−2〜2−4及び比較例2 炭酸水素ナトリウムと結晶セルロースの重量を以下の表
2のように変えた以外は実施例1−1と同様にして錠剤
を得、溶出試験を実施した。結果を図2に示した。Examples 2-2 to 2-4 and Comparative Example 2 Tablets were obtained and dissolved in the same manner as in Example 1-1 except that the weights of sodium hydrogen carbonate and crystalline cellulose were changed as shown in Table 2 below. The test was performed. The results are shown in FIG.
【0026】[0026]
【表2】 [Table 2]
【0027】実施例3−1 当帰芍薬散エキス錠 当帰芍薬散エキス末 83.33重量% 炭酸水素ナトリウム 14.17重量%(当帰芍
薬散エキス末に対して約17.00%) 結晶セルロース 2.00重量% ステアリン酸マグネシウム 0.50重量% 上記原料を用い、実施例1−1と同様にして錠剤を得、
溶出試験を実施した。結果を図3に示した。Example 3-1 Tokishakuyakusan extract tablet Tokishakuyakusan extract powder 83.33% by weight 14.17% by weight of sodium bicarbonate (about 17.00% based on Tokishakuyakusan extract powder) Cellulose 2.00% by weight Magnesium stearate 0.50% by weight Using the above raw materials, tablets were obtained in the same manner as in Example 1-1.
A dissolution test was performed. The results are shown in FIG.
【0028】実施例3−2〜3−8及び比較例3 炭酸水素ナトリウムと結晶セルロースの重量を以下の表
3のように変えた以外は実施例1−1と同様にして錠剤
を得、溶出試験を実施した。結果を図3に示した。Examples 3-2 to 3-8 and Comparative Example 3 Tablets were obtained and dissolved in the same manner as in Example 1-1 except that the weights of sodium hydrogen carbonate and crystalline cellulose were changed as shown in Table 3 below. The test was performed. The results are shown in FIG.
【0029】[0029]
【表3】 [Table 3]
【0030】実施例4 防巳黄ぎ湯エキス錠 防巳黄ぎ湯エキス末 74.00重量% 炭酸水素ナトリウム 25.00重量%(防巳黄
ぎ湯エキス末に対して約33.78%) ステアリン酸マグネシウム 1.00重量% 上記原料を用い、実施例1−1と同様にして錠剤を得、
溶出試験を実施した。結果を図4に示した。Example 4 Homi-kogi-to extract powder 74.00% by weight of antimi-gogi-to extract powder 25.00% by weight of sodium hydrogen carbonate (approximately 33.78% with respect to the anti-mi-gogi-to extract powder) 1.00% by weight of magnesium stearate Using the above raw materials, a tablet was obtained in the same manner as in Example 1-1,
A dissolution test was performed. The results are shown in FIG.
【0031】比較例4 炭酸水素ナトリウムの代りに結晶セルロースを使用した
以外は実施例1−1と同様にして錠剤を得、溶出試験を
実施した。結果を図4に示した。Comparative Example 4 A tablet was obtained and a dissolution test was carried out in the same manner as in Example 1-1 except that crystalline cellulose was used instead of sodium hydrogen carbonate. The results are shown in FIG.
【0032】実施例5−1 牛車腎気丸エキス錠 牛車腎気丸エキス末 72.50重量% 炭酸水素ナトリウム 10.00重量%(牛車腎
気丸エキス末に対して約13.79%) 結晶セルロース 17.00重量% ステアリン酸マグネシウム 0.50重量% 上記原料を用い、実施例1−1と同様にして錠剤を得、
溶出試験を実施した。結果を図5に示した。Example 5-1 Gushi-Carne Ki-Gan Extract Powder 72.50% by weight of Gushi-Carne Ki-Gan Extract Powder 10.00% by weight of sodium bicarbonate (about 13.79% based on Gushi-Carne Ki-Gan Extract Powder) Cellulose 17.00% by weight Magnesium stearate 0.50% by weight Using the above raw materials, a tablet was obtained in the same manner as in Example 1-1.
A dissolution test was performed. The results are shown in FIG.
【0033】実施例5−2、3及び比較例5 炭酸水素ナトリウムと結晶セルロースの重量を以下の表
4のように変えた以外は実施例1−1と同様にして錠剤
を得、溶出試験を実施した。結果を図5に示した。Examples 5-2, 3 and Comparative Example 5 Tablets were obtained in the same manner as in Example 1-1 except that the weights of sodium hydrogen carbonate and crystalline cellulose were changed as shown in Table 4 below, and a dissolution test was performed. Carried out. The results are shown in FIG.
【0034】[0034]
【表4】 [Table 4]
【0035】実施例6 桂枝ぶく苓丸料エキス錠 桂枝ぶく苓丸料エキス末 56.00% 炭酸水素ナトリウム 10.00% 結晶セルロース 33.50% ステアリン酸マグネシウム 0.50% 上記原料を用い、実施例1−1と同様にして錠剤を得
た。Example 6 Keishi-bukuryo pill extract powder Keishi-buku-ryo pill extract powder 56.00% sodium bicarbonate 10.00% crystalline cellulose 33.50% magnesium stearate 0.50% And a tablet was obtained in the same manner as in Example 1-1.
【0036】実施例7 小青竜湯エキス錠 小青竜湯エキス末 75.00% 炭酸水素ナトリウム 12.00% 結晶セルロース 12.50% ステアリン酸マグネシウム 0.50% 上記原料を用い、実施例1−1と同様にして錠剤を得
た。Example 7 Shoseiryuto extract powder Shoseiryuto extract powder 75.00% Sodium bicarbonate 12.00% Crystalline cellulose 12.50% Magnesium stearate 0.50% In the same manner as in -1, a tablet was obtained.
─────────────────────────────────────────────────────
────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成9年11月7日[Submission date] November 7, 1997
【手続補正1】[Procedure amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】図面の簡単な説明[Correction target item name] Brief description of drawings
【補正方法】追加[Correction method] Added
【補正内容】[Correction contents]
【図面の簡単な説明】[Brief description of the drawings]
【図1】実施例1−1〜1−4及び比較例1の溶出試験
の結果を表すグラフである。FIG. 1 is a graph showing the results of a dissolution test of Examples 1-1 to 1-4 and Comparative Example 1.
【図2】実施例2−1〜2−4及び比較例2の溶出試験
の結果を表すグラフである。FIG. 2 is a graph showing the results of dissolution tests of Examples 2-1 to 2-4 and Comparative Example 2.
【図3】実施例3−1〜3−8及び比較例3の溶出試験
の結果を表すグラフである。FIG. 3 is a graph showing the results of a dissolution test of Examples 3-1 to 3-8 and Comparative Example 3.
【図4】実施例4及び比較例4の溶出試験の結果を表す
グラフである。FIG. 4 is a graph showing the results of a dissolution test of Example 4 and Comparative Example 4.
【図5】実施例5−1〜5−3及び比較例5の溶出試験
の結果を表すグラフである。FIG. 5 is a graph showing the results of a dissolution test of Examples 5-1 to 5-3 and Comparative Example 5.
フロントページの続き (72)発明者 丸山 英之 茨城県稲敷郡阿見町吉原3586 株式会社ツ ムラ内Continued on the front page (72) Inventor Hideyuki Maruyama 3586 Yoshiwara, Ami-cho, Inashiki-gun, Ibaraki Pref.
Claims (7)
り、薬効成分の溶出性を向上させたことを特徴とする錠
剤組成物。Claims: 1. A tablet composition characterized in that the dissolution of a pharmaceutically active ingredient is improved by blending sodium bicarbonate.
壊時間が5分以上である錠剤組成物に対し、炭酸水素ナ
トリウムを配合することにより、薬効成分の溶出性を向
上させたことを特徴とする錠剤組成物。2. In the disintegration test described in the Japanese Pharmacopoeia, the dissolution property of a medicinal component is improved by adding sodium hydrogen carbonate to a tablet composition having a disintegration time of 5 minutes or more. Tablet composition.
種以上である請求項1又は2に記載の錠剤組成物。3. The medicinal component is one or two of natural component-derived components.
The tablet composition according to claim 1 or 2, which is at least one species.
項3に記載の錠剤組成物。4. The tablet composition according to claim 3, wherein the component derived from a natural product is a plant extract.
項3に記載の錠剤組成物。5. The tablet composition according to claim 3, wherein the component derived from a natural product is a Kampo extract.
う辛夷、乙字湯、安中散、十味敗毒湯、八味地黄丸、大
柴胡湯、小柴胡湯、柴胡桂枝湯、柴胡加竜骨牡蛎湯、半
夏瀉心湯、黄連解毒湯、半夏厚朴湯、五苓散、小青竜
湯、防己黄ぎ湯、消風散、当帰芍薬散、加味逍遥散、桂
枝茯苓丸、桂枝加竜骨牡蛎湯、麻黄湯、麦門冬湯、四逆
散、苓桂じゅつ甘湯、補中益気湯、桂枝湯、七物降下
湯、十全大補湯、荊芥連翹湯、清上防風湯、防風通聖
散、女神散、芍薬甘草湯、平胃散、大黄甘草湯、当帰飲
子、六味丸、治打撲一方、小建中湯、大建中湯、辛夷清
肺湯、牛車腎気丸、柴苓湯、茯苓飲合半夏厚朴湯、黄連
湯、当帰建中湯、桂枝茯苓丸加よく苡仁、麻子仁丸、麻
黄附子細辛湯、桂枝加芍薬大黄湯、清暑益気湯、桔梗湯
等である請求項5に記載の錠剤組成物。6. The herbal extract is Kakkon-to, Kakkon-to-Kagawa Kyu-Shin-i, Oji-ji-to, Annaka-san, Jumi-toxin-to, Hachimi-jio-gan, Dai-saiko-to, Sho-saiko-to, Saiko-keishi-to, Saiko-to Karyukotsuboreito, Hangeshashinto, Oren-dokuto, Hangesatsu-koboku, Goreisan, Shoseiryuto, Boku-ki-goto, Shofu-san, Toki-Shakuyaku-san, Kami-shoyo-san, Keishi-bukuryo-maru , Keishi-ka-ryukotsuboreito, Mao-to, Bakumondo-to, Shigyakusan, Ryokei-jutsu-kan-yu, Hochu-ekki-to, Keishi-to, Shichimono-descent-to, Juzen-taiho-to, Jingaku-ren-yo , Seikatsu Hofuyu, Hofutsu Seisho, Meishan, Shakuyaku kanzoto, Hiragansan, Daiokanzoto, Toki Yoko, Rokumimaru, Jiji-Hatsu, Shokenchuto, Daikenchuto, Shinyaku Hot water, beef cart Nekkiki-maru, Saireito, Bukuryo-drinking Hankato, Oren-to, Tokikenchu-to, Keishi-bukuryo-maru-ka-yokujin, Asako-inmaru, Mao-bushi-saishin-to, Keishi-ka-shakuyaku 6. The method according to claim 5, which is Taikyo-to, Seishatsu-ekki-to, Kikyo-to, etc. Tablet composition.
分の重量に対し3%以上である請求項1又は2に記載の
錠剤組成物。7. The tablet composition according to claim 1, wherein the amount of sodium hydrogencarbonate is 3% or more based on the weight of the active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23771097A JP4122544B2 (en) | 1997-08-18 | 1997-08-18 | Tablet composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23771097A JP4122544B2 (en) | 1997-08-18 | 1997-08-18 | Tablet composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH1160504A true JPH1160504A (en) | 1999-03-02 |
JP4122544B2 JP4122544B2 (en) | 2008-07-23 |
Family
ID=17019361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP23771097A Expired - Lifetime JP4122544B2 (en) | 1997-08-18 | 1997-08-18 | Tablet composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4122544B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004006945A1 (en) * | 2002-07-12 | 2004-01-22 | Tsumura & Co. | Tablet composition containing chinese orthodox medicine extract and process for producing the same |
WO2009093736A1 (en) * | 2008-01-25 | 2009-07-30 | Kobayashi Pharmaceutical Co., Ltd. | Tablet comprising kanpo herbal medicine and pantethine component |
JP2009242328A (en) * | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | Bofutusyosan-blended preparation |
JP5344289B2 (en) * | 2006-06-29 | 2013-11-20 | 株式会社ツムラ | Kampo extract-containing tablet composition |
JP2017043589A (en) * | 2015-08-28 | 2017-03-02 | 中野Bc株式会社 | Solid agent and method for producing the same |
WO2018236125A1 (en) * | 2017-06-20 | 2018-12-27 | 정희태 | Method for converting, into aconine, diester-diterpenoid alkaloids and monoester-diterpenoid alkaloids, highly toxic substances contained in aconitum carmichaeli debeauxor aconite tuber |
-
1997
- 1997-08-18 JP JP23771097A patent/JP4122544B2/en not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004006945A1 (en) * | 2002-07-12 | 2004-01-22 | Tsumura & Co. | Tablet composition containing chinese orthodox medicine extract and process for producing the same |
US7326427B2 (en) | 2002-07-12 | 2008-02-05 | Tsumura & Co. | Tablet composition containing Kampo medicinal extract and its manufacturing process |
JP4774739B2 (en) * | 2002-07-12 | 2011-09-14 | 株式会社ツムラ | Kampo extract-containing tablet composition and method for producing the same |
JP5344289B2 (en) * | 2006-06-29 | 2013-11-20 | 株式会社ツムラ | Kampo extract-containing tablet composition |
WO2009093736A1 (en) * | 2008-01-25 | 2009-07-30 | Kobayashi Pharmaceutical Co., Ltd. | Tablet comprising kanpo herbal medicine and pantethine component |
JP2009242328A (en) * | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | Bofutusyosan-blended preparation |
JP2017043589A (en) * | 2015-08-28 | 2017-03-02 | 中野Bc株式会社 | Solid agent and method for producing the same |
WO2018236125A1 (en) * | 2017-06-20 | 2018-12-27 | 정희태 | Method for converting, into aconine, diester-diterpenoid alkaloids and monoester-diterpenoid alkaloids, highly toxic substances contained in aconitum carmichaeli debeauxor aconite tuber |
Also Published As
Publication number | Publication date |
---|---|
JP4122544B2 (en) | 2008-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100634253B1 (en) | Formulation of Fast-Dissolving Efavirenz Capsules or Tablets Using Super-Disintegrants | |
KR100384264B1 (en) | Manufacturing method of dosage unit by wet granulation | |
WO2003041700A1 (en) | Storage stable thyroxine active drug formulations | |
EP0991415B1 (en) | Orally administrable solid ribavirin dosage forms and process for making them | |
WO2007086891A1 (en) | Levetiracetam formulations and methods for their manufacture | |
JP2012025778A (en) | Fenofibrate-containing composition | |
JP5344289B2 (en) | Kampo extract-containing tablet composition | |
JP2017061576A (en) | Solid composition | |
JPH1160504A (en) | Tablet composition | |
JP2007161706A (en) | Antyusan-containing tablet | |
JP6373616B2 (en) | Oral composition | |
JPH1121236A (en) | Loxoprofen-sodium solid preparation | |
CN1042492C (en) | Preparing method for apovincamine acid ethyl ester | |
WO2000071117A1 (en) | Immediate release medicinal compositions for oral use | |
NO325154B1 (en) | Coated cyclophosphamide tablets, process for the preparation of tablet cores and film tablets, and tablet core and film tablets obtained by these methods | |
JP4504467B2 (en) | Orally disintegrating tablets | |
US20050163868A1 (en) | Tablet composition containing chinese orthodox medicine extract and process for producing the same | |
KR20190007370A (en) | Combination formulation having improved stability and dissolution rate comprising Bazedoxifene or its pharmaceutically acceptable salt, and Cholecalciferol or its pharmaceutically acceptable salt | |
CN102349882A (en) | Medicinal composition containing trandolapril and preparation process thereof | |
CN101427992B (en) | Clopidogrel hydrobromate preparation and method of producing the same | |
CN101926782B (en) | Oral solid drug compound containing dienogest | |
KR100788454B1 (en) | Rapid-acting fomulation containing nateglinide as an active ingredient | |
KR20160140567A (en) | Pharmaceutical composition comprising oseltamivir free base | |
WO2021097651A1 (en) | Pharmaceutical composition comprising orlistat and plant-derived lipase inhibitor | |
WO2022172076A1 (en) | Preparation of microwave dried novel co-processed excipient of sucrose and tablet formulation of canagliflozin tablets using co- processed excipient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070717 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070914 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080408 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080421 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110516 Year of fee payment: 3 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070914 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140516 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |